Investments – LSI Zeta

CubaseBio enables true 3D spatial analysis at scale, unlocking unprecedented biological insights and accelerating drug discovery.

Specializing in the development of next generation single domain antibodies. Mesenkia is a pre-clinical company developing the next-generation biological drug candidates designed to treat the aggressive brain tumor glioblastoma.

Solid IO is developing a patient-specific tumor-on-chip platform that uses living tumor tissue to predict how individual cancer patients will respond to different therapies. By enabling functional drug testing before treatment begins, the company aims to improve outcomes and accelerate the adoption of precision oncology.

StemSight develops off-the-shelf regenerative cell therapies for corneal blindness. Our expertise is in the combination of iPS-derived cells with functional biomaterials – for faster tissue regeneration, safer cell therapies and easier cell delivery.